Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial.
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial.
复制标题
胆碱稳定的原硅酸补充剂作为钙/维生素D3的辅助性刺激骨质减少性雌性中骨形成的标志物：一项随机的，安慰剂对照试验。
DOI：
10.1186/1471-2474-9-85
复制
发表时间：
2008-06-11
影响因子：
2.3
通讯作者：
Powell, Jonathan J.
中科院分区：
文献类型：
--
作者：
Spector, Tim D.;Calomme, Mario R.;Anderson, Simon H.;Clement, Gail;Bevan, Liisa;Demeester, Nathalie;Swaminathan, Rami;Jugdaohsingh, Ravin;Vanden Berghe, Dirk A.;Powell, Jonathan J.
越来越多的证据支持硅(Si)作为正硅酸(OSA，Si(OH)4)在骨形成中的生理作用。采用双盲安慰剂对照试验，研究了口服胆碱稳定的正硅酸(ch-OSA)对骨转换指标和骨密度(BMD)的影响。在12个月的时间里，随机抽样(T-Score脊柱-1.5)中的136名妇女完成了这项研究，每天服用1000毫克钙和20μ克胆钙化醇(VitD3)和三种不同剂量的胆钙素(3，6和12毫克硅)或安慰剂。在基线、6个月和12个月后测定血清和尿骨吸收标志物中的骨形成标志物。分别于治疗前和治疗12个月后行双能X线骨密度仪测定股骨和腰椎骨密度。总体而言，ch-OSA有为钙和VitD3治疗带来一些额外益处的趋势，特别是骨形成的标志物，但只有I型胶原形成的标志物(PINP)在12个月时对于6 mg和12 mg硅剂量(与安慰剂相比)是显著的，没有明显的剂量反应效应。骨吸收标记物I型胶原C端肽(CTX-I)有随剂量相应增加的趋势。腰椎骨密度无明显变化。然而，对于股骨颈6 mg剂量(T检验)，后组分组分析(基准T-Score股骨)是显着的。未观察到与ch-OSA相关的不良反应，生化安全指标维持在正常范围。与单独应用Ca/VitD3相比，ch-OSA和Ca/VitD3联合治疗对骨胶原有潜在的有利作用，提示该疗法在治疗骨质疏松方面有潜在的应用价值。NTR 1029
Mounting evidence supports a physiological role for silicon (Si) as orthosilicic acid (OSA, Si(OH)4) in bone formation. The effect of oral choline-stabilized orthosilicic acid (ch-OSA) on markers of bone turnover and bone mineral density (BMD) was investigated in a double-blind placebo-controlled trial. Over 12-months, 136 women out of 184 randomized (T-score spine < -1.5) completed the study and received, daily, 1000 mg Ca and 20 μg cholecalciferol (Vit D3) and three different ch-OSA doses (3, 6 and 12 mg Si) or placebo. Bone formation markers in serum and urinary resorption markers were measured at baseline, and after 6 and 12 months. Femoral and lumbar BMD were measured at baseline and after 12 months by DEXA. Overall, there was a trend for ch-OSA to confer some additional benefit to Ca and Vit D3 treatment, especially for markers of bone formation, but only the marker for type I collagen formation (PINP) was significant at 12 months for the 6 and 12 mg Si dose (vs. placebo) without a clear dose response effect. A trend for a dose-corresponding increase was observed in the bone resorption marker, collagen type I C-terminal telopeptide (CTX-I). Lumbar spine BMD did not change significantly. Post-hoc subgroup analysis (baseline T-score femur < -1) however was significant for the 6 mg dose at the femoral neck (T-test). There were no ch-OSA related adverse events observed and biochemical safety parameters remained within the normal range. Combined therapy of ch-OSA and Ca/Vit D3 had a potential beneficial effect on bone collagen compared to Ca/Vit D3 alone which suggests that this treatment is of potential use in osteoporosis. NTR 1029
登录
查看更多内容
影响因子：
3.9
作者：
Calomme, MR;VandenBerghe, DA
通讯作者：
VandenBerghe, DA
影响因子：
39.2
作者：
Grady, D;Wenger, NK;Hulley, S
通讯作者：
Hulley, S
影响因子：
6.2
作者：
Bauer, DC;Black, DM;Delmas, PD
通讯作者：
Delmas, PD
影响因子：
7
作者：
Eisman, JA
通讯作者：
Eisman, JA
影响因子：
6.2
作者：
Loty, C;Sautier, JM;Forest, N
通讯作者：
Forest, N